Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Alopecia areata is a non-scarring hair loss disorder that affects both sexes equally. Incidence of the disease varies for different populations and in different studies, with global incidence ranging from 0.57% to 3.8%.

Etiology of alopecia areata is not completely understood, and the majority of evidence suggests that genetically predisposed individuals, when exposed to an unknown trigger, develop a predominantly autoimmune reaction, leading to acute hair loss. Environmental triggers, including viral or bacterial infections, along with autoimmune disorders, seem to play a major role in the development of alopecia areata.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Ergocalciferols; Pharmaceutical Solutions; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• patients with refractory alopecia areata above 10 years old

Exclusion Criteria:

• Alopecia totalis or alopecia universalis.

• Patients with alopecia other than alopecia areata.

• Patients younger than 10 years.

• Pregnant and lactating females.

• Patients with history of hypertrophic scars or keloid formation.

• Patients with active infection at the site of the lesion.

• Patients with blood disorders and platelet abnormalities and chronic liver disease.

• Patients using anticoagulation therapy and antiplatelet agents.